XML Financial LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

XML Financial LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,044 shares of the biopharmaceutical company’s stock after selling 63 shares during the quarter. XML Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $744,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $49,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $680.03 on Thursday. The firm has a fifty day simple moving average of $733.06 and a 200-day simple moving average of $943.95. The company has a market capitalization of $74.73 billion, a PE ratio of 16.83, a price-to-earnings-growth ratio of 1.61 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Finally, Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.